Vous êtes sur la page 1sur 2

An Introduction to Molecular Oncology 1. TP53 in cancer origin and treatment (PCG 91, MHBC 100) a. Discovery b. Function c.

Type of genetic changes: i. Mutation ii. Functional: MDM2, HPV E6, dll (MBHC p.108) d. Inherited p53 mutation: LFS. Genetical landmark, very diverse, li-fraumeni-like 2. Apoptosis & Senescence (Mol Bio Hum Ca) a. Definition b. Genes related: RB, p53, CDK, BCL-2 c. Mechanisms, caspases, death receptor, NF-kb, apoptosis inducing factors d. Mechanism for diminished apoptosis e. Necrosis, difference, mechanism, and its relation to cancer f. Polygenicity, selective pressure dihub dgn senescence 3. Cancer Biology: Cell growth, Metabolism, proliferation, Microenvironment, Angiogenesis, Invasion and Metastasis a. Microenvironment: i. stroma as active contributor, not passive medium, makrofag, fibroblast, CXCL-12, TGF-b, MMP (Mol Basis of Ca) b. hormonal effect c. Steps in invasion and metastasis d. What drives cell to invasion and metastasize e. Molecular aspect of Cell-to-cell and cell-matrix adhesion, extracellular matrix, gene related f. Metastatic genetic determinants: Suppressor and Induction g. Metastatic cascade, Organ-selectivity (Tumor-stroma interaction) h. Angiogenesis: angiogenic switch, difference with Normal angiogenesis, pro-anti angiogenic factors, i. Failure of Immune system to counter cancer cell, mechanism 4. Cancer Stem Cells (Shi Ming Tu dan Sadhan) a. Historical Perspectives b. Cancer Stem Cell Model of Carcinogenesis c. Theory of origin of CSC: embryonal rest theory, dedifferentiation theory d. Teratocarcinoma and CSC e. Properties of CSC f. Targeting CSC for Therapy 5. Molecular Diagnostics a. Biomarkers trends b. Screening c. Early Diagnosis d. Staging / Classification e. Bioinformatics 6. Molecular Genetic Testing in Genomic Era

Nucleic Acid Extraction PCR Qualitative Analysis Real Time PCR Sequencing Analysis Pyrosequencing Promotor Hypermethilation: i. Multiplex PCR and Fragmen Analysis ii. HRM h. MLPA 7. Molecular Basis of Cancer Therapy a. Principles of Ca Chemotherapy (Rachel Airley) b. Classic Chemotherapy: alkylating agent, antimetabolit, hormonal, agent derived from natural or semisynthetic products (antitumor antibiotic, groove binding, inhibitor topoisomerase, dll) (Rachel Airley) c. Molecular Targeted Therapy and Personalized Medicine i. How to develop new drugs ii. Defining new cancer-relevant target: antibodies, immunotoxin, gene therapy, RNAi d. Novel Chemotherapies i. Antiangiogenic and antivascular agent ii. Tyrosin kinase inhibitor iii. Ras inhibitor iv. Inhibitor of Akt/PKB pathway v. Heat Shock Protein Inhibitor vi. Telomerase vii. Histone Deacytelase viii. Checkpoint protein kinase

a. b. c. d. e. f. g.

Vous aimerez peut-être aussi